Morgan Stanley Cuts Envista (NYSE:NVST) Price Target to $19.00

Envista (NYSE:NVST) had its price target lowered by Morgan Stanley from $20.00 to $19.00 in a research report released on Thursday,Benzinga reports. Morgan Stanley currently has an equal weight rating on the stock.

NVST has been the subject of a number of other reports. Needham & Company LLC reissued a “hold” rating on shares of Envista in a research note on Thursday. Piper Sandler raised their target price on Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, February 3rd. Mizuho assumed coverage on shares of Envista in a report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price target for the company. Wells Fargo & Company boosted their price objective on shares of Envista from $20.00 to $21.00 and gave the stock an “equal weight” rating in a report on Thursday, February 6th. Finally, Jefferies Financial Group increased their target price on shares of Envista from $20.00 to $22.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.38.

Envista Price Performance

Envista stock opened at $18.47 on Thursday. The business has a 50 day simple moving average of $20.22 and a 200-day simple moving average of $19.69. Envista has a 12 month low of $15.15 and a 12 month high of $23.00. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. The stock has a market capitalization of $3.18 billion, a PE ratio of -2.85, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33.

Envista (NYSE:NVST) last issued its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Equities analysts predict that Envista will post 1 earnings per share for the current year.

Institutional Trading of Envista

Institutional investors and hedge funds have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC raised its stake in Envista by 11.2% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 15,314 shares of the company’s stock valued at $303,000 after purchasing an additional 1,538 shares during the last quarter. State of Alaska Department of Revenue raised its position in shares of Envista by 7.3% in the third quarter. State of Alaska Department of Revenue now owns 19,887 shares of the company’s stock valued at $392,000 after buying an additional 1,355 shares during the last quarter. US Bancorp DE lifted its stake in shares of Envista by 150.6% during the third quarter. US Bancorp DE now owns 4,971 shares of the company’s stock valued at $98,000 after buying an additional 2,987 shares during the period. Assetmark Inc. boosted its position in Envista by 5.9% during the third quarter. Assetmark Inc. now owns 38,641 shares of the company’s stock worth $764,000 after acquiring an additional 2,152 shares during the last quarter. Finally, Covestor Ltd grew its stake in Envista by 34.2% in the 3rd quarter. Covestor Ltd now owns 6,359 shares of the company’s stock worth $125,000 after acquiring an additional 1,621 shares during the period.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.